Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study

Andres Acosta, Michael Camilleri, Duane Burton, Jessica O'Neill, Deborah Eckert, Paula Carlson, Alan R Zinsmeister, Andres Acosta, Michael Camilleri, Duane Burton, Jessica O'Neill, Deborah Eckert, Paula Carlson, Alan R Zinsmeister

Abstract

Obesity is associated with differences in satiety, gastric emptying (GE), gastric volume, and psychological traits. Exenatide, a short-acting glucagon-like peptide 1 (GLP-1) receptor agonist, is associated with variable weight loss. We compared the effects of exenatide, 5 μg, and placebo SQ, twice daily for 30 days on GE of solids and liquids (scintigraphy), satiety (ad libitum buffet meal), satiation (nutrient drink test, maximum tolerated volume [MTV]), and weight loss in 20 participants with documented accelerated GE of solids (T1/2 < 90 min). Exenatide delayed GE of solids (T1/2 [Δ] 86 min relative to placebo, P < 0.001) and reduced calorie intake at buffet meal ([Δ] 129 kcal compared to placebo). Median weight loss was -0.95 kg (IQR -0.7 to -2.1) for exenatide and -0.55 kg (0.3 to -2.1) for placebo (P = 0.23); 80% of exenatide group had documented reduction in weight. In the exenatide treatment group, there was an inverse correlation between gastric emptying T1/2 and MTV (R = -0.548, P = 0.089). The univariate association of weight change with posttreatment MTV was borderline (Rs = 0.43, P = 0.06); in the multiple regression model, posttreatment MTV was associated with weight change (P = 0.047). The effect of the short-acting GLP-1 receptor agonist, exenatide, on GE is associated with the change in food intake, and the latter impacts weight loss in response to exenatide treatment.

Keywords: Glucagon‐like peptide 1; pharmacogenomics; satiation.

© 2015 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of the American Physiological Society and The Physiological Society.

Figures

Figure 1
Figure 1
Consort diagram.
Figure 2
Figure 2
Effect of exenatide on gastric emptying in obese patients with previously documented accelerated gastric emptying (P < 0.001 for both [A] gastric emptying proportion at 1 h and [B] gastric emptying T1/2). Data show median, IQR, and range. (C) Each individual’s gastric emptying measurements at prior study on no treatment (“baseline”) and on treatment in the current study are plotted. (D) The rate of gastric emptying per group. (E) An illustrative scintigraphic image of gastric emptying at 3 h in placebo versus exenatide, with stomach area demarcated in yellow.
Figure 3
Figure 3
Effect of exenatide on body weight. Data shown are medians (IQR).
Figure 4
Figure 4
(A) Relationship of gastric emptying and maximum tolerated volume (MTV) in patients treated with exenatide (−r = −0.548; P = 0.089). (B) In a multiple regression model, including gastric emptying and satiation parameters, posttreatment MTV was modestly associated with weight change (P = 0.047).

References

    1. Acosta A, Abu Dayyeh BK, Port JD. Camilleri M. Recent advances in clinical practice challenges and opportunities in the management of obesity. Gut. 2014a;63:687–695.
    1. Acosta A, Camilleri M, Shin A, Carlson P, Burton D, O’Neill J, et al. Association of melanocortin 4 receptor gene variation with satiation and gastric emptying in overweight and obese adults. Genes Nutr. 2014b;9:384–390.
    1. Acosta A, Camilleri M, Shin A, Vazquez-Roque M, Iturrino J, Burton D, et al. Candidate genes and quantitative gastrointestinal traits in obesity. Obesity. 2015a (abstract, in press, 2015)
    1. Acosta A, Camilleri M, Shin A, Vazquez-Roque MI, Iturrino J, Burton D, et al. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy. Gastroenterology. 2015b;148:537–546. e4.
    1. Andrews CN, Bharucha AE, Camilleri M, Low PA, Seide B, Burton D, et al. Nitrergic contribution to gastric relaxation induced by glucagon-like peptide-1 (GLP-1) in healthy adults. Am. J. Physiol. 2007;292:G1359–G1365.
    1. Bray G. Ryan D. Update on obesity pharmacotherapy. Ann. N. Y. Acad. Sci. 2014;1311:1–13.
    1. Camilleri M, Iturrino J, Bharucha AE, Burton D, Shin A, Jeong ID, et al. Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants. Neurogastroenterol. Motil. 2012;24:1076–1083. e562.
    1. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE. Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int. J. Obes. 2014;38:784–793.
    1. Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am. J. Physiol. 2008;294:E846–E852.
    1. Chial HJ, Camilleri C, Delgado-Aros S, Burton D, Thomforde G, Ferber I, et al. A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health. Neurogastroenterol. Motil. 2002;14:249–253.
    1. Cremonini F, Mullan BP, Camilleri M, Burton DD. Rank MR. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment. Pharmacol. Ther. 2002;16:1781–1790.
    1. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH. MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr. Med. Res. Opin. 2008;24:2943–2952.
    1. Delgado-Aros S, Kim D-Y, Burton D, Thomforde G, Stephens D, Brinkmann B, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am. J. Physiol. 2002;282:G424–G431.
    1. Dushay J, Gao C, Gopalakrishnan GS, Crawley M, Mitten EK, Wilker E, et al. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care. 2011;35:4–11.
    1. Flegal KM, Carroll MD, Kit BK. Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307:491–497.
    1. Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M. Knudsen LB. Liraglutide: short-lived effect on gastric emptying – long lasting effects on body weight. Diabetes Obes. Metab. 2012;14:531–538.
    1. Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul. Pept. 2008;151:123–129.
    1. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2012;8:728–742.
    1. Meier JJ, Rosenstock J, Hincelin-Méry A, Roy-Duval C, Delfolie A, Coester HV, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38:1263–1273.
    1. Moreno J, Willett K. Desilets A. Exenatide as a novel weight loss modality in patients without diabetes. Ann. Pharmacother. 2012;46:1700–1706.
    1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:766–781.
    1. Peters A. Incretin-based therapies: review of current clinical trial data. Am. J. Med. 2010;123:S28–S37.
    1. Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care. 2010;33:1173–1175.
    1. Schirra J, Kuwert P, Wank U, Leicht P, Arnold R, Goke B, et al. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc. Assoc. Am. Physicians. 1997;109:84–97.
    1. Schirra J, Wank U, Arnold R, Goke B. Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut. 2002;50:341–348.
    1. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut. 2006;55:243–251.
    1. Schirra J, Nicolaus M, Woerle HJ, Struckmeier C, Katschinski M. Goke B. GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastroenterol. Motil. 2009;21:609–618. e21–22.
    1. Umapathysivam MM, Lee MY, Jones KL, Annink CE, Cousins CE, Trahair LG, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014;63:785–790.
    1. Vazquez-Roque MI, Camilleri M, Stephens DA, Jensen MD, Burton DD, Baxter KL, et al. Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people. Gastroenterology. 2006;131:1717–1724.
    1. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans. J. Clin. Endocrinol. Metab. 2001;86:4382–4389.
    1. Vilsbøll T, Christensen M, Junker AE, Knop FK. Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi